Revenio Group

32,04EUR +0,5 %
13 312 investerare följer bolaget.

Revenio är verksamma inom medicinteknik. Inom koncernen återfinns forskning och utveckling av tryckmätningsteknik som används vid behandling av ett flertal sjukdomar som glaukom, osteoporos, hudcancer samt astma. Verksamhet innehas på global nivå och drivs via flertalet dotterbolag med vardera affärsinriktning. Bolagets huvudkontor ligger i Vantaa.

P/E (23e)
33,74
EV/EBIT (23e)
25,71
P/B (23e)
8,08
Direktavkastnings- % (23e)
1,27 %
Riktkurs
38.00 EUR
Rekommendation
Minska
Uppdaterad
27.4.2023
NASDAQ Helsinki
REG1V
Dagens lägsta / högsta pris
31,74 / 32,14 EUR
Börsvärde
854,86 mn EUR
Omsättning
938,64 tn EUR
Volym
29 tn
Risk och rekommendation
HögRiskLåg
SäljRekommendationKöp

Resultaträkning

20192020202120222023e2024e2025e2026e
Omsättning49,4761,0578,8097,00110,84129,08150,98176,79
tillväxt-%61,36 %23,41 %29,07 %23,10 %14,27 %16,46 %16,96 %17,10 %
EBITDA14,5921,7025,7033,1236,0941,9249,9260,16
EBIT15,5819,2024,5330,8833,3939,1446,7656,62
EBIT12,5917,1022,1029,6832,1937,9845,5655,47
Vinst före skatt12,2716,7022,1029,0831,4837,7945,5755,69
Nettoresultat9,3613,3517,3021,7824,0429,1035,0942,88
EPS0,470,580,740,860,951,141,371,66
tillväxt-%39,39 %22,54 %27,24 %16,94 %9,81 %19,88 %19,94 %21,36 %
Utdelning0,300,320,340,360,410,550,730,97
Utdelningskvot85,12 %63,73 %52,44 %43,93 %45,00 %50,00 %55,00 %60,00 %

Lönsamhet och avkastning på kapital

20192020202120222023e2024e2025e2026e
EBITDA-%29,50 %35,53 %32,61 %34,14 %32,56 %32,48 %33,07 %34,03 %
EBIT-%31,49 %31,44 %31,13 %31,84 %30,13 %30,33 %30,97 %32,03 %
EBIT-%25,46 %28,00 %28,05 %30,60 %29,04 %29,43 %30,18 %31,37 %
ROE22,71 %19,92 %23,36 %25,73 %24,50 %25,41 %26,20 %27,49 %
ROI22,41 %17,93 %22,07 %27,57 %27,70 %29,06 %30,47 %32,42 %

Värdering

20192020202120222023e2024e2025e2026e
Pris per aktie (EUR)26,2550,3055,5538,6032,0432,0432,0432,04
Aktier26,5426,5826,6826,5826,5826,5826,5826,58
Börsvärde696,801 336,921 482,141 026,00851,64851,64851,64851,64
Rörelsevärde699,701 334,921 482,031 014,56827,59807,03786,33763,67
EV/S14,1421,8718,8110,467,476,255,214,32
EV/EBITDA47,9561,5357,6730,6422,9319,2515,7512,69
EV/EBIT44,9269,5560,4232,8524,7820,6216,8213,49
EV/EBIT55,5678,0967,0634,1825,7121,2517,2613,77
P/E (just.)55,3586,5675,1344,6433,7428,1523,4719,34
P/E73,01100,1885,6747,1035,4329,2724,2719,86
P/B10,8419,1818,9011,298,086,895,915,08
P/S14,0921,9018,8110,587,686,605,644,82
Direktavkastning1,14 %0,64 %0,61 %0,93 %1,27 %1,71 %2,27 %3,02 %
Soliditet58,56 %60,93 %63,02 %66,79 %70,35 %72,01 %73,33 %74,44 %
Gearing ratio4,67 %−2,73 %−12,48 %−22,73 %−35,99 %−45,22 %−52,37 %

Quarter data

Q2/22Q3/22Q4/222022Q1/23Q2/23eQ3/23eQ4/23e2023e
Omsättning24,4124,1228,2897,0023,2027,1428,4032,10110,84
EBITDA7,988,5310,2233,127,088,518,8811,6336,09
EBIT7,137,669,3429,686,187,517,8810,6332,19
Vinst före skatt7,087,618,5929,085,777,417,7810,5331,48
Nettoresultat5,426,085,7221,784,245,705,998,1124,04
Publisher
Applications of AI-aided iCare ILLUME screening solution are expanding

The development of the iCare ILLUME solution has been fast and the pilots have quickly progressed to actual customer use in Europe, which also means (so far small) income flow to the company. The path from a growth initiative to a medium-term growth driver seems to progress very well in Europe based on the first examples, but the steps are still unclear in the US.

Analytikerkommentar2023-06-08 av Juha Kinnunen
Publisher
Revenio: The story progresses on track

Q1 results were slightly below our expectations, but the outlook is unchanged, and we think the value creator story is on track. The challenge is again the high valuation (2023e EV/EBIT above 30x) and hence the moderate expected return.

Aktieanalys2023-04-28 av Juha Kinnunen
Publisher
Revenio Q1 on Thursday: Net sales growth on track

We expect the company's net sales to continue to grow at a brisk pace, with profitability expected to remain largely unchanged, so earnings will grow broadly in line with net sales. We don’t expect significant changes in the market situation, so the demand situation should remain good. In addition to the development of the core business, we are interested in comments on the development of the company's new growth initiatives (in particular HOME2 and ILLUME).

Analytikerkommentar2023-04-24 av Juha Kinnunen
Publisher
Revenio: Holistic value creation on the horizon

Under the iCare brand, Revenio offers world-class tonometers, fundus imaging devices and perimeters. In recent years, the company has added software solutions to its offering, moving from being an equipment provider to a holistic eye diagnostics solution provider.

Omfattande aktieanalys2023-03-18 av Juha Kinnunen